Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 7/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | GAA | P10253 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 8/20 | 0.43 |
| ▸ | MAPT | P10636 | 7/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 3/20 | 0.41 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | APEX1 | P27695 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4168555 | 0.89 | LMNA (0.47) | MEN1KMT2AALDH1A1GAALMNA | |
| SCHEMBL5166506 | 0.85 | RAB9A (0.47) | MEN1KMT2AALDH1A1GAALMNA | |
| SCHEMBL5167718 | 0.82 | RAB9A (0.44) | MEN1KMT2AALDH1A1GAALMNA | |
| SCHEMBL5165817 | 0.82 | MEN1 (0.43) | MEN1KMT2AALDH1A1GAALMNA | |
| SCHEMBL5163176 | 0.81 | NPC1 (0.41) | MEN1KMT2AALDH1A1GAALMNA | |
| SCHEMBL5163999 | 0.81 | MEN1 (0.44) | MEN1KMT2AALDH1A1GAALMNA | |
| Oxyquinoline SCHEMBL5165186 | 0.80 | MMP2 (0.46) | MEN1KMT2AALDH1A1LMNAMAPT | |
| SCHEMBL5167091 | 0.80 | ALDH1A1 (0.46) | MEN1KMT2AALDH1A1GAALMNA | |
| SCHEMBL4169579 | 0.79 | LMNA (0.48) | MEN1KMT2AALDH1A1LMNAMAPT | |
| SCHEMBL4169850 | 0.79 | LMNA (0.51) | MEN1KMT2AALDH1A1GAALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1765360-A2 | ANTI-VIRAL USES OF BORINIC ACID COMPLEXES | Anacor Pharmaceuticals, Inc. (US) | 2007-03-28 | — | — | EP | claimed |
| WO-2006085932-A2 | ANTI-VIRAL USES OF BORINIC ACID COMPLEXES | ANACOR PHARMACEUTICALS, INC. (US) | 2006-08-17 | — | — | WO | claimed |
| US-20060019927-A1 | Anti-viral uses of borinic acid complexes | ANACOR PHARMACEUTICALS, INC. | 2006-01-26 | — | — | US | claimed |
| US-7393856-B2 | Anti-viral uses of borinic acid complexes | ANACOR PHARMACEUTICALS, INC. (US) | 2008-07-01 | — | — | US | disclosed |
| EP-1771182-A1 | ANTI-PARASITIC USES OF BORINIC ACID COMPLEXES | Anacor Pharmaceuticals, Inc. (US) | 2007-04-11 | — | — | EP | disclosed |
| EP-1765360-A2 | ANTI-VIRAL USES OF BORINIC ACID COMPLEXES | Anacor Pharmaceuticals, Inc. (US) | 2007-03-28 | — | — | EP | disclosed |
| WO-2006085932-A2 | ANTI-VIRAL USES OF BORINIC ACID COMPLEXES | ANACOR PHARMACEUTICALS, INC. (US) | 2006-08-17 | — | — | WO | disclosed |
| US-20060019927-A1 | Anti-viral uses of borinic acid complexes | ANACOR PHARMACEUTICALS, INC. | 2006-01-26 | — | — | US | disclosed |
| US-20060014723-A1 | Anti-parasitic uses of borinic acid complexes | ANACOR PHARMACEUTICALS, INC. | 2006-01-19 | — | — | US | disclosed |
| WO-2005123095-A1 | ANTI-PARASITIC USES OF BORINIC ACID COMPLEXES | ANACOR PHARMACEUTICALS, INC. (US) | 2005-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014723-A1 | Anti-parasitic uses of borinic acid complexes | BPGM, HRH1, HRH3 | MEN1 1345/4885KMT2A 3687/4885ALDH1A1 2879/4885 |
| US-20060019927-A1 | Anti-viral uses of borinic acid complexes | SSB, BPGM, HAVCR2 | MEN1 1740/4885KMT2A 4230/4885ALDH1A1 3836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.